Functional Imaging and Theranostics

ACC overview

Functional imaging in ACC is easiest to interpret when FDG-PET is kept distinct from emerging receptor- or fibroblast-directed scans and from the broader theranostic question of whether imaging can select treatment rather than only describe disease.¹²³

Diagnostic Map

FDG PET for Staging and Recurrence in ACC

This note covers the most mature functional-imaging use case in ACC: diagnostic characterization, staging, recurrence assessment, and prognostic enrichment with FDG PET/CT.¹²³

Grouped note: FDG PET for Staging and Recurrence in ACC

Emerging Receptor and Theranostic Imaging in ACC

These articles track metomidate-family tracers, CXCR4, FAPI, somatostatin-receptor imaging, and other approaches that may support theranostic selection.¹²³

Grouped note: Emerging Receptor and Theranostic Imaging in ACC

Functional Imaging for Response Assessment in ACC

This cluster focuses on whether functional imaging can outperform anatomy alone when tracking treatment response or identifying biologically active residual disease.¹²³

Grouped note: Functional Imaging for Response Assessment in ACC

How to Read This Literature

The grouped notes below separate established PET use from newer tracers and from papers that try to link uptake patterns to therapy selection.¹²³

See Also

• anatomic_imaging
• precision_medicine_and_biomarker_development
• targeted_therapy

References

Footnotes

1. Detection of metastatic adrenal carcinoma using 131I-6-beta-iodomethyl-19-norcholesterol total body scans.. J Clin Endocrinol Metab. 1977. PMID: 410824. Local full text: 410824.md ↩ ↩² ↩³ ↩⁴ ↩⁵

2. Adrenal scintigraphy with 131I-19-iodochlesterol in the diagnosis of Cushing’s syndrome associated with adrenal tumor.. Eur J Nucl Med. 1979. PMID: 520360. Local full text: 520360.md ↩ ↩² ↩³ ↩⁴ ↩⁵

3. Scintigraphic detection of hepatic metastases with 131I-labeled steroid in recurrent adrenal carcinoma: case report.. J Nucl Med. 1976. PMID: 966060. Local full text: 966060.md ↩ ↩² ↩³ ↩⁴ ↩⁵